Population-based maximum tolerated dose of irinotecan and carboplatin.

Oncology (Williston Park, N.Y.)

Volumn 17, Issue 7 Suppl 7, 2003, Pages 11-16

  Wild, Carolyn A ^a   Wang, Stephen E ^a   Gandara, David R ^a   Lara Jr , Primo N ^a   Meyers, Frederick J ^a   Tanaka Jr , Michael ^a   Houston, Joan ^a   Lauder, Jun ^a   Lau, Derick H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DRUG DERIVATIVE; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0142058822     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)